Nov 29, 2023 / 04:00PM GMT
David A. Amsellem - Piper Sandler & Co., Research Division - MD & Senior Research Analyst
Okay. Good morning, everyone, and let's get started. Welcome again to the 35th Annual Piper Sandler Healthcare Conference. I'm David Amsellem from the pharma team. And with us is Organon. We have Kevin Ali, CEO; and Matt Walsh, CFO. Thanks gentlemen, for joining us. And certainly, lots to talk about, so I'm going to dive right in with questions here.
Kevin Ali - Organon & Co. - CEO & Director
Go ahead.
Questions and Answers:
David A. Amsellem - Piper Sandler & Co., Research Division - MD & Senior Research AnalystSo I'll start at a high level and ask how you're thinking about balancing debt paydown and capital deployment to bolster the pipeline and/or commercial portfolio. So maybe I'll start with you, Kevin.
Kevin Ali - Organon & Co. - CEO & Director
You jumping right in the deep end first?
David A. Amsellem - Piper